Spero Reports Preliminary Findings From Phase 1 Clinical Trial Of SPR206 Suggesting It Is Well-Tolerated At Doses Within Therapeutic Range For Target And Plans To Advance Program With Alliance Partners Everest Medicines And The Department Of Defense